<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650737</url>
  </required_header>
  <id_info>
    <org_study_id>ESPB in nephrolithotomy</org_study_id>
    <nct_id>NCT04650737</nct_id>
  </id_info>
  <brief_title>Single-Shot With Dexmedetomidine Versus Continuous Ultrasound-guided Erector Spinae Plane Block for Postoperative Pain Control After Percutaneous Nephrolithotomy</brief_title>
  <official_title>Single-Shot With Dexmedetomidine Versus Continuous Ultrasound-guided Erector Spinae Plane Block for Postoperative Pain Control After Percutaneous Nephrolithotomy Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to assess the efficacy of a single shot ESPB with&#xD;
      Dexmedetomidineversus continuous ESPB in perioperative analgesia for PCNL. Both techniques&#xD;
      are conducted for patients undergoing PCNL under GA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Successful perioperative pain management is one of the main goals of the whole anesthetic&#xD;
      practice. Kidney Surgeries, especially those involving the renal pelvis warrant special&#xD;
      analgesic considerations. This is due to the sensitivity of the renal pelvis to pain. Its&#xD;
      sub-diaphragmatic position affects deep breathing and coughing. Which renders adequate&#xD;
      analgesia an important factor for maintaining good respiratory force and depth postoperative&#xD;
      and reduces respiratory complications like atelectasis.&#xD;
&#xD;
      The Use of a single mode of analgesia in these settings , like the use of parenteral opioids&#xD;
      for example, provides significantly less analgesic effect and more complications including&#xD;
      respiratory depression , PONV (postoperative nausea and vomiting ) , constipation , urine&#xD;
      retention …etc.&#xD;
&#xD;
      The use of regional techniques as a part of multimodal pain management in these procedures&#xD;
      provides superior analgesia and less complication rates.&#xD;
&#xD;
      This is added to high expectations of an easier perioperative course of PCNL (percutaneous&#xD;
      nephrolithotomy) being and endoscopic procedure that does not involve a big skin incision.&#xD;
      These expectations also include a short hospital stay. However PCNL is usually associated&#xD;
      with significant pain and discomfort postoperatively. Various studies have been studying&#xD;
      effects of integrating local and regional techniques in the perioperative pain management.&#xD;
&#xD;
      For Regional and local procedures of analgesia; Studies of Single Shot technique and catheter&#xD;
      techniques has long been ongoing for many regional techniques for example like Pravertebral&#xD;
      block and adductor canal block . These studies are conducted to determine the efficacy and&#xD;
      adversities each technique.&#xD;
&#xD;
      Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of&#xD;
      peripheral nerve block . Dexmedetomidine is a more potent and selective α-2-adrenoceptor&#xD;
      compared to clonidine . Peri-neural dexmedetomidine was evaluated in animal studies where it&#xD;
      prolonged the duration of sensory and motor blocks of local anesthetics without any evidence&#xD;
      of neurotoxicity for up to 14 days after initial administration . The use of&#xD;
      perineuraldexmedetomidine prolong the duration of of sensory block, provide effective acute&#xD;
      pain control after surgery and reduce the need for rescue analgesia in several nerve blocks&#xD;
      like upper limb extremity blocks,Paravertebral block), tranversus abdominis plane (TAP) block&#xD;
      and Erector spinae plane block.&#xD;
&#xD;
      Erector spinae plane block (ESPB) is a relatively novel procedure. The limited number of&#xD;
      studies available show promising results as regards the efficacy of pain management in trunk&#xD;
      surgeries and renal interventions. However the studies that clarify the different&#xD;
      applications of ESPB, including the efficacy of a single shot versus a continuous block with&#xD;
      an indwelling catheter, are lacking.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Both groups will receive Ultrasound guided ESPB before induction of general anesthesia&#xD;
Single shot group (A):(20 patients) Patients in this group will receive 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine.&#xD;
Continous infusion group (B):(20 patients) Patients in this group will receive 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of postoperative Analgesia:</measure>
    <time_frame>post-operative period(24 hours)</time_frame>
    <description>&quot;the time interval between extubation and the first request to postoperative analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of sensory block</measure>
    <time_frame>24 hours</time_frame>
    <description>the time interval between the onset of successful sensory block and the first request to postoperative analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale from 1 to 10,while 10 is the worst pain at rest and movement</measure>
    <time_frame>24 hours</time_frame>
    <description>visual analogue scale during rest and movement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Stone, Kidney</condition>
  <arm_group>
    <arm_group_label>Group A (single shot,n=20)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine ;ultrasound guided ESPB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (continous infusion,n=20)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs;ESPB</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single shot ESBP with dexmedtomidine</intervention_name>
    <description>Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine</description>
    <arm_group_label>Group A (single shot,n=20)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continous ESPB</intervention_name>
    <description>Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.</description>
    <arm_group_label>Group B (continous infusion,n=20)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients of age (18-50), ASA physical status I or II undergoing unilateral&#xD;
             percutaneous nephrolithotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Body mass index greater than 35 kg/m2.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Unstable coronary artery disease, congestive heart failure, or arrhythmias.&#xD;
&#xD;
          -  Baseline heart rate (HR) less than 60 beats/min or baseline systolic blood pressure&#xD;
             less than 100 mmHg.&#xD;
&#xD;
          -  Pre-existing neurological deficits or neuropathy.&#xD;
&#xD;
          -  Significant psychiatric or cognitive conditions interfering with consent or&#xD;
             assessment.&#xD;
&#xD;
          -  Significant renal impairment (creatinine above 2 mg/dl)&#xD;
&#xD;
          -  Severe bronchopulmonary disease, including chronic obstructive pulmonary disease and&#xD;
             obstructive sleep apnea.&#xD;
&#xD;
          -  Known contraindications to peripheral nerve block, including local skin infections,&#xD;
             bleeding diathesis, and coagulopathy.&#xD;
&#xD;
          -  Allergies to local anesthetics, dexmedetomidine, or any component of multimodal&#xD;
             analgesia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Arshad Z, Zaidi SZ, Jamshaid A, Qureshi AH. Post operative pain control in percutaneous nephrolithotomy. J Pak Med Assoc. 2018 May;68(5):702-704.</citation>
    <PMID>29885165</PMID>
  </reference>
  <reference>
    <citation>Schug SA, Fry RA. Continuous regional analgesia in comparison with intravenous opioid administration for routine postoperative pain control. Anaesthesia. 1994 Jun;49(6):528-32.</citation>
    <PMID>8017600</PMID>
  </reference>
  <reference>
    <citation>Choi SW, Cho SJ, Moon HW, Lee KW, Lee SH, Hong SH, Choi YS, Bae WJ, Ha US, Hong SH, Lee JY, Kim SW, Cho HJ. Effect of Intercostal Nerve Block and Nephrostomy Tract Infiltration With Ropivacaine on Postoperative Pain Control After Tubeless Percutaneous Nephrolithotomy: A Prospective, Randomized, and Case-controlled Trial. Urology. 2018 Apr;114:49-55. doi: 10.1016/j.urology.2017.12.004. Epub 2017 Dec 27.</citation>
    <PMID>29288788</PMID>
  </reference>
  <reference>
    <citation>Pöpping DM, Elia N, Marret E, Wenk M, Tramèr MR. Clonidine as an adjuvant to local anesthetics for peripheral nerve and plexus blocks: a meta-analysis of randomized trials. Anesthesiology. 2009 Aug;111(2):406-15. doi: 10.1097/ALN.0b013e3181aae897. Review.</citation>
    <PMID>19602964</PMID>
  </reference>
  <reference>
    <citation>Farag E, Argalious M, Abd-Elsayed A, Ebrahim Z, Doyle DJ. The use of dexmedetomidine in anesthesia and intensive care: a review. Curr Pharm Des. 2012;18(38):6257-65. Review.</citation>
    <PMID>22762468</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mina Adolf Helmy</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

